New developments in understanding the etiology of Parkinson's disease and in its treatment

Current Opinion in Neurobiology

Volumn 8, Issue 6, 1998, Pages 783-790

  Lozano, Andres M ^a   Lang, Anthony E ^b   Hutchison, William D ^b   Dostrovsky, Jonathon O ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CARBIDOPA; CLOZAPINE; FLUOXETINE; LEVODOPA; PROPRANOLOL DERIVATIVE; SELEGILINE;

AGRANULOCYTOSIS; BASAL GANGLION; GENE ISOLATION; GENE THERAPY; GLOBUS PALLIDUS; HUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0031701839     PISSN: 09594388     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-4388(98)80122-0     Document Type: Article

References (68)

1. German DC, Schlusselberg DS, Woodward DJ. Three-dimensional computer reconstruction of midbrain dopaminergic neuronal populations: from mouse to man. J Neural Transm. 57:1983;243-254.
2. Burke RE. Programmed cell death and Parkinson's disease. Mov Disord. 13:1998;17-23. (suppl 1).
3. Offen D, Beart PM, Cheung NS, Pascoe CJ, Hochman A, Gorodin S, Melamed E, Bernard R, Bernard O. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Proc Natl Acad Sci USA. 95:1998;5789-5794.
4. Hirsch EC, Faucheux BA. Iron metabolism and Parkinson's disease. Mov Disord. 13:1998;39-45. (suppl 1).
5. Jenner P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord. 13:1998;24-34. (suppl 1).
6. Schapira AH. Pathogenesis of Parkinson's disease. Baillieres Clin Neurol. 6:1997;15-36.
7. Speciale SG, Liang CL, Sonsalla PK, Edwards RH, German DC. The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter. Neuroscience. 84:1998;1177-1185.
8. Uhl GR. Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Ann Neurol. 43:1998;555-560.
9. Smidt MP, Van Schaick HS, Lanctot C, Tremblay JJ, Cox JJ, Van Der Kleij, Wolterink G, Drouin J, Burbach JP. A homeodomain gene Ptx3 has highly restricted brain expression in mesencephalic dopaminergic neurons. Proc Natl Acad Sci USA. 94:1997;13305-13310.
10. Mouatt-Prigent A, Agid Y, Hirsch EC. Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease? Brain Res. 666:1994;62-70.
11. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. of outstanding interest Science. 276:1997;2045-2047 The authors report the first mutation identified in families with Parkinson's disease. Understanding the molecular pathogenesis of the α-synuclein mutation will provide important insights into the etiology of genetic and so-called sporadic causes of PD.
12. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. of outstanding interest Nature. 388:1997;839-840 α-Synuclein is a major component of Lewy bodies in PD and in Diffuse Lewy Body disease. This finding provides an important clue to the pathogenesis of PD. The role of synuclein aggregates in neuronal cell death is not yet known.
13. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. of outstanding interest Nature. 392:1998;605-608 The authors report the identification of a mutation in the parkin gene that causes autosomal recessive parkinsonism. This paper provides an important window into a distinct form of parkinsonism with a different molecular pathogenesis.
14. Wichmann T, DeLong MR. Models of basal ganglia function and pathophysiology of movement disorders. Neurosurg Clin N Am. 9:1998;223-236.
15. Levy R, Hazrati LN, Herrero MT, Vila M, Hassani OK, Mouroux M, Ruberg M, Asensi H, Agid Y, Feger J, et al. Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states. Neuroscience. 76:1997;335-343.
16. Mink JW. The basal ganglia: focused selection and inhibition of competing motor programs. Prog Neurobiol. 50:1996;381-425.
17. Smith Y, Shink E, Sidibe M. Neuronal circuitry and synaptic connectivity of the basal ganglia. of special interest Neurosurg Clin N Am. 9:1998;203-222 An excellent summary of our current understanding of the basal ganglia circuitry, including newly described pathways.
18. Bergman H, Feingold A, Nini A, Raz A, Slovin H, Abeles M, Vaadia E. Physiological aspects of information processing in the basal ganglia of normal and parkinsonian primates. Trends Neurosci. 21:1998;32-38.
19. Hutchison WD, Levy R, Dostrovsky JO, Lozano AM, Lang AE. Effects of apomorphine on globus pallidus neurons in parkinsonian patients. of special interest Ann Neurol. 42:1997;767-775 Single-unit recordings in PD patients reveals that apomorphine reduces GPi but increases GPe, firing rates. The findings suggest that, as in parkinsonian non-human primates, GPi is overactive in PD patients, that dopamine agonists reduce this excessive activity, and that reductions in GPi firing are associated with improvements in akinesia and rigidity.
20. Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Silbersweig D, Stern E, Woods RP, Fazzini E, Dogali M, Beric A. Regional metabolic correlates of surgical outcome following unilateral pallidotomy for Parkinson's disease. Ann Neurol. 39:1996;450-459.
21. Bergman H, Wichmann T, Karmon B, DeLong MR. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol. 72:1994;507-520.
22. Hutchison WD, Allan RJ, Opitz J, Levy R, Dostrovsky JO, Lang AE, Lozano AM. Neurophysiologic identification of the subthalamic nucleus in surgery for Parkinson's disease. Ann Neurol. 44:1998;622-628.
23. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 328:1993;176-183.
24. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol. 39:1996;37-45.
25. Mytilineou C, Radcliffe PM, Olanow CW. L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro. J Neurochem. 68:1997;434-436.
26. Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. BMJ. 311:1995;1602-1607.
27. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. of special interest Ann Neurol. 43:1998;318-325 The Parkinson study group evaluated the mortality of the DATATOP cohort so as to provide further data to compare to the worrisome results of a UK study [26] finding a significantly increased mortality rate in combined treatments of selegiline and levodopa. This study did not find that the combination of selegiline and levodopa is associated with an increase in mortality in PD patients; however, this study used a different population of patients from the UK study [26].
28. Agid Y. Levodopa: is toxicity a myth? of special interest Neurology. 50:1998;858-863 This is an excellent review of the issues related to levodopa toxicity, which concludes that there is no clinical or experimental evidence to support the concern that levodopa is toxic to dopaminergic neurons.
29. Murer MG, Dziewczapolski G, Menalled LB, Garcia MC, Agid Y, Gershanik O, Raisman-Vozari R. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. of outstanding interest Ann Neurol. 43:1998;561-575 An important study that evaluates the effects of levodopa in rats with partial and severe nigrostriatal lesions. In the rats with partial lesions, levodopa has a trophic rather than a toxic effect on the remaining dopaminergic neurons.
30. Miyawaki E, Lyons K, Pahwa R, Troster AI, Hubble J, Smith D, Busenbark K, McGuire D, Michalek D, Koller WC. Motor complications of chronic levodopa therapy in Parkinson's disease. of special interest Clin Neuropharmacol. 20:1997;523-530 A good, up-to-date review of the frequency of levodopa complications in a large clinical population of PD patients.
31. Chase TN, Engber TM, Mouradian MM. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Adv Neurol. 69:1996;497-501.
32. Block G, Liss C, Reines S, Irr J, Nibbelink D, Aarli J, Aguilar M, Ahrens S, Bakheit A, Baumel B. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease - a multicenter 5-year study. Eur Neurol. 37:1997;23-27.
33. Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, Taylor RL, Sanchez-Ramos J, O'Brien CF. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group Neurology. 49:1997;393-399.
34. Shannon KM, Bennett JPJ, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group Neurology. 49:1997;724-728.
35. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Masso JFM, Montastruc JL, Marsden CD, Dubini A, Orlando N, et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology. 48:1997;363-368.
36. Kurth MC, Adler CH, Hilaire MS, Singer C, Waters C, Lewitt P, Chernik DA, Dorflinger EE, Yoo K. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I Neurology. 48:1997;81-87.
37. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol. 42:1997;747-755.
38. Carpentier AF, Bonnet AM, Vidalhet M, Agid Y. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease. Neurology. 46:1996;1548-1551.
39. Durif F, Vidailhet M, Bonnet AM, Blin J, Agid Y. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology. 45:1995;1855-1858.
40. Durif F, Vidailhet M, Assal F, Roche C, Bonnet AM, Agid Y. Low-dose clozapine improves dyskinesias in Parkinson's disease. Neurology. 48:1997;658-662.
41. Verhagen ML, Del DP, Van DM, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. of special interest Neurology. 50:1998;1323-1326 The authors describe a new use for an old, and usually well tolerated, drug, amantadine. Its antidyskinetic effect may be related to its anti-NMDA effects, which may also underlie its overall anti-Parkinson effects.
42. Factor SA, Friedman JH. The emerging role of clozapine in the treatment of movement disorders. Mov Disord. 12:1997;483-496.
43. Wolters EC, Jansen ENH, Tuynman-Qua HG, Bergmans PLM. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology. 47:1996;1085-1087.
44. Rascol O, Blin O, Descombes S, Soubrouillard C, Fabre N, Viallet F, Thalamas C, Azulay JP, Lafnitzegger K, Fedrick E, et al. ABT-431, a selective D1 agonist has efficacy in patients with Parkinson's disease. Neurology. 48:1996;A269-A270.
45. Belluzzi JD, Domino EF, May JM, Bankiewicz KS, McAfee DA. N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease. Mov Disord. 9:1994;147-154.
46. Richardson PJ, Kase H, Jenner PG. Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol Sci. 18:1997;338-344.
47. Hughes NR, McKnight AT, Woodruff GN, Hill MP, Crossman AR, Brotchie JM. Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism. Mov Disord. 13:1998;228-233.
48. Williams M, Wright S, Lloyd GK. Improved therapies for Parkinson's disease: life beyond dopamine D2/D3 receptor agonists. of special interest Trends Pharmacol Sci. 18:1997;307-310 An excellent survey of some new pharmacological avenues being explored for the future treatment of Parkinson's disease.
49. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol. 39:1996;574-578.
50. Steiner JP, Hamilton GS, Ross DT, Valentine HL, Guo HZ, Connolly MA, Liang S, Ramsey C, Li JHJ, Huang W, et al. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. of outstanding interest Proc Natl Acad Sci USA. 94:1997;2019-2024 The identification of neurotrophic immunophilins is potentially one of the most important new developments in the field of treatment of neurodegenerative diseases. The authors demonstrate the protective and regenerative effects of neurotrophic immunophilin ligands in culture and in animal models of PD.
51. Koller W, Pahwa R, Busenbark K, Hubble J, Wilkinson S, Lang A, Tuite P, Sime E, Lozano AM, Hauser R, et al. High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Ann Neurol. 42:1997;292-299.
52. Gross C, Rougier A, Guehl D, Boraud T, Julien J, Bioulac B. High frequency stimulation of the globus pallidus internalis in Parkinson's disease: a study of seven cases. of special interest J Neurosurg. 87:1997;491-498 Reports that stimulation of GPi produces striking improvements in the major signs of PD.
53. Krack P, Limousin P, Benabid AL, Pollak P. Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson's disease. of special interest Lancet. 350:1997;1676 The authors report that chronic subthalamic stimulation has an unexpected anti-dyskinetic effect. The diminution in dyskinesias may be related to the important reduction in medications made possible by the anti-parkinsonian effect of the surgery.
54. Davis KD, Taub E, Houser D, Lang AE, Dostrovsky JO, Tasker R, Lozano A. Globus pallidus stimulation activates the cortical motor system during alleviation of parkinsonian symptoms. of special interest Nat Med. 3:1997;671-674 Globus pallidus stimulation, like pallidotomy, activates the cortical supplementary motor area. This finding suggests that pallidal stimulation acts as a reversible pallidal lesion.
55. Krack P, Pollak P, Limousin P, Benazzouz A, Benabid AL. Stimulation of subthalamic nucleus alleviates tremor in Parkinson's disease. of outstanding interest Lancet. 350:1997;1675 STN stimulation produces striking improvements in parkinsonian signs, including tremor. This is the first paper to report the use of the STN nucleus as a surgical target for the treatment of PD tremor.
56. Pahwa R, Wilkinson S, Smith D, Lyons K, Miyawaki E, Koller WC. High-frequency stimulation of the globus pallidus for the treatment of Parkinson's disease. of special interest Neurology. 49:1997;249-253 Reports that high-frequency GPi stimulation is an alternative to pallidotomy as a treatment of PD.
57. Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg. 76:1992;53-61.
58. Lang AE, Lozano AM, Montgomery E, Duff J, Tasker R, Hutchison W. Posteroventral medial pallidotomy in advanced Parkinson's disease. of special interest N Engl J Med. 337:1997;1036-1042 Reports the results of a large trial of microelectrode-guided unilateral pallidotomy showing improvements in the major manifestations of PD and increased independence in patients with advanced PD.
59. Kishore A, Turnbull IM, Snow BJ, De La Fuente-Fernandez R, Schulzer M, Mak E, Yardley S, Calne DB. Efficacy, stability and predictors of outcome of pallidotomy for Parkinson's disease - six-month follow-up with additional 1-year observations. of special interest Brain. 120:1997;729-737 The authors report good clinical benefits using (non-microelectrode recording guided) unilateral pallidotomy. This surgical technique, which does not rely on a detailed physiologic localization of the sensorimotor territory of GPi, can also produce substantial motor improvements.
60. Baron MS, Vitek JL, Bakay RA, Green J, Kaneoke Y, Hashimoto T, Turner RS, Woodard JL, Cole SA, McDonald WM, DeLong MR. Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1-year results of a pilot study. Ann Neurol. 40:1996;355-366.
61. Ondo WG, Jankovic J, Lai EC, Sankhla C, Khan M, Ben-Arie L, Schwartz K, Grossman RG, Krauss JK. Assessment of motor function after stereotactic pallidotomy. Neurology. 50:1998;266-270.
62. Kordower JH, Freeman TB, Snow BJ, Vingerhoets FJG, Mufson EJ, Sanberg PR, Hauser RA, Smith DA, Nauert GM, Perl DP, Olanow CW. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med. 332:1995;1118-1124.
63. Isacson O, Deacon TW, Pakzaban P, Galpern WR, Dinsmore J, Burns LH. Transplanted xenogeneic neural cells in neurodegenerative disease models exhibit remarkable axonal target specificity and distinct growth patterns of glial and axonal fibres. Nat Med. 1:1995;1189-1194.
64. Schumacher JM, Isacson O. Neuronal xenotransplantation in Parkinson's disease. Nat Med. 3:1997;474-475.
65. Gash DM, Zhang ZM, Ovadia A, Cass WA, Yi A, Simmerman L, Russell D, Martin D, Lapchak PA, Collins F, et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature. 380:1996;252-255.
66. Espejo EF, Montoro RJ, Armengol JA, Lopez-Barneo J. Cellular and functional recovery of Parkinsonian rats after intrastriatal transplantation of carotid body cell aggregates. Neuron. 20:1998;197-206.
67. Sautter J, Tseng JL, Braguglia D, Aebischer P, Spenger C, Seiler RW, Widmer HR, Zurn AD. Implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor improve survival, growth, and function of fetal dopaminergic grafts. Exp Neurol. 149:1998;230-236.
68. Kang UJ. Gene therapy for Parkinson's disease: neurobiologic issues and new developments in gene transfer methodologies. of special interest Mov Disord. 1998; An excellent review of gene therapy techniques in animal models of PD.